Literature DB >> 19538237

Quality of life after islet transplantation: data from the GRAGIL 1 and 2 trials.

P Y Benhamou1, L Milliat-Guittard, A Wojtusciszyn, L Kessler, C Toso, R Baertschiger, I Debaty, L Badet, A Penfornis, C Thivolet, E Renard, F Bayle, P Morel, E Morelon, C Colin, T Berney.   

Abstract

BACKGROUND: Rigorous assessment of health-related quality of life (HRQL) is mandatory to establish the benefits of islet transplantation.
METHODS: The 36-Item Short Form Health Survey (SF-36) and the Diabetes Quality of Life (DQOL) scales were completed by patients included in an Islet Transplantation Alone (ITA) trial (n = 10) and an Islet After Kidney (IAK) trial (n = 10).
RESULTS: The two populations differed by HRQL scores at baseline, with poorer scores in ITA patients. SF-36 scores for physical limitations, bodily pain, general health perception, social functioning, and health transition improved significantly in ITA patients 6 and 12 months post transplantation. The DQOL global score was significantly improved at 6 months and remained so at 12 months, because of a significant improvement in the dimensions of satisfaction and impact of diabetes. No improvement was observed in the IAK patients.
CONCLUSION: HRQL assessment may help in the selection of candidates with brittle diabetes for islet transplantation.

Entities:  

Mesh:

Year:  2009        PMID: 19538237     DOI: 10.1111/j.1464-5491.2009.02731.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  14 in total

Review 1.  Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes.

Authors:  Carmen Fotino; Camillo Ricordi; Vincenzo Lauriola; Rodolfo Alejandro; Antonello Pileggi
Journal:  Rev Diabet Stud       Date:  2010-08-10

2.  25 YEARS OF THE RICORDI AUTOMATED METHOD FOR ISLET ISOLATION.

Authors:  Lorenzo Piemonti; Antonello Pileggi
Journal:  CellR4 Repair Replace Regen Reprogram       Date:  2013

Review 3.  Minireview: beta-cell replacement therapy for diabetes in the 21st century: manipulation of cell fate by directed differentiation.

Authors:  Vijay Yechoor; Lawrence Chan
Journal:  Mol Endocrinol       Date:  2010-03-10

Review 4.  Immunological Monitoring in Beta Cell Replacement: Towards a Pathophysiology-Guided Implementation of Biomarkers.

Authors:  Fanny Buron; Sophie Reffet; Lionel Badet; Emmanuel Morelon; Olivier Thaunat
Journal:  Curr Diab Rep       Date:  2021-04-25       Impact factor: 4.810

5.  Concerns and hopes of patients with type 1 diabetes prior to islet cell transplantation: A content analysis.

Authors:  Queena F Luu; Celine J Villareal; Cynthia Fritschi; Rebecca S Monson; Jose Oberholzer; Kirstie K Danielson
Journal:  J Diabetes Complications       Date:  2018-04-17       Impact factor: 2.852

6.  Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia.

Authors:  Eric D Foster; Nancy D Bridges; Irene D Feurer; Thomas L Eggerman; Lawrence G Hunsicker; Rodolfo Alejandro
Journal:  Diabetes Care       Date:  2018-03-21       Impact factor: 19.112

7.  Islet cell transplant: Update on current clinical trials.

Authors:  Christian Schuetz; James F Markmann
Journal:  Curr Transplant Rep       Date:  2016-05-17

Review 8.  Islet assessment for transplantation.

Authors:  Klearchos K Papas; Thomas M Suszynski; Clark K Colton
Journal:  Curr Opin Organ Transplant       Date:  2009-12       Impact factor: 2.640

Review 9.  Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: A Clinical Evidence Review.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2015-09-01

Review 10.  Felix dies natalis, insulin… ceterum autem censeo "beta is better".

Authors:  Lorenzo Piemonti
Journal:  Acta Diabetol       Date:  2021-05-23       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.